Shuang Cai

ORCID: 0000-0003-2976-6918
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Nanoparticle-Based Drug Delivery
  • Nanoplatforms for cancer theranostics
  • Cancer Cells and Metastasis
  • Cancer Treatment and Pharmacology
  • Photodynamic Therapy Research Studies
  • RNA modifications and cancer
  • Proteoglycans and glycosaminoglycans research
  • Immunotherapy and Immune Responses
  • RNA Interference and Gene Delivery
  • Veterinary Oncology Research
  • Epigenetics and DNA Methylation
  • Cancer, Hypoxia, and Metabolism
  • Angiogenesis and VEGF in Cancer
  • Glycosylation and Glycoproteins Research
  • Advanced biosensing and bioanalysis techniques
  • Cancer-related gene regulation
  • Metabolism, Diabetes, and Cancer
  • Advanced Proteomics Techniques and Applications
  • Lymphatic System and Diseases
  • Peptidase Inhibition and Analysis
  • Cancer-related molecular mechanisms research
  • Genetics and Neurodevelopmental Disorders
  • Cancer Research and Treatments
  • Ubiquitin and proteasome pathways
  • Breast Cancer Treatment Studies

China Medical University
2013-2025

First Hospital of China Medical University
2013-2025

University of Kansas Medical Center
2007-2025

Xi'an Jiaotong University
2021-2024

Huazhong University of Science and Technology
2021-2023

China Agricultural University
2023

Institute of Genetics and Developmental Biology
2022

Hubei University of Arts and Science
2022

University of Kansas
2009-2021

Union Hospital
2021

Robert A. Holt G. Subramanian Aaron L. Halpern Granger G. Sutton Rosane Charlab and 95 more Deborah Nusskern Patrick Wincker Andrew G. Clark José M. C. Ribeiro Ron Wides Steven L. Salzberg Brendan Loftus Mark Yandell William H. Majoros Douglas B. Rusch Zhongwu Lai Cheryl Kraft Josep F. Abril Véronique Anthouard Peter Arensburger Peter W. Atkinson Holly Baden Véronique de Berardinis Danita Baldwin Vladimı́r Beneš Jim Biedler Claudia Blass Randall Bolanos Didier Boscus Mary Barnstead Shuang Cai Angela Center Kabir Chatuverdi George K. Christophides Mathew A. Chrystal Michèle Clamp Anibal Cravchik Val Curwen Ali Dana Art L. Delcher Ian Dew Cheryl Evans Michael J. Flanigan Anne Grundschober-Freimoser Lisa Friedli Zhiping Gu Ping Guan Roderic Guigó Maureen E. Hillenmeyer Susanne L. Hladun James R. Hogan Young Seok Hong Jeffrey P. Hoover Olivier Jaillon Zhaoxi Ke Chinnappa D. Kodira E. B. Kokoza Anastasios C. Koutsos Ivica Letunić Alex Levitsky Yong Liang Jing‐Jer Lin Neil F. Lobo John Lopez Joel A. Malek Tina C. McIntosh Stephan Meister Jason Miller Clark Mobarry Emmanuel Mongin Sean D. Murphy David A. O’Brochta Cynthia Pfannkoch Rong Qi Megan A. Regier Karin Remington Hongguang Shao Maria V. Sharakhova Cynthia D. Sitter Jyoti Shetty Thomas J. Smith Renee Strong Jing‐Tao Sun Dana Thomasová Lucas Q. Ton Pantelis Topalis Zhijian Tu Maria Unger Brian P. Walenz Aihui Wang Jian Wang Mei Wang Xuelan Wang Kerry J. Woodford Jennifer R. Wortman Martin Wu Alison Yao Evgeny M. Zdobnov Zhang HongYu Qi Zhao

Anopheles gambiae is the principal vector of malaria, a disease that afflicts more than 500 million people and causes 1 deaths each year. Tenfold shotgun sequence coverage was obtained from PEST strain A. assembled into scaffolds span 278 base pairs. A total 91% genome organized in 303 scaffolds; largest scaffold 23.1 There substantial genetic variation within this strain, apparent existence two haplotypes approximately equal frequency ("dual haplotypes") fraction likely reflects outbred...

10.1126/science.1076181 article EN Science 2002-10-03

10.1016/j.cell.2016.05.069 article EN publisher-specific-oa Cell 2016-07-01

The Clinical Proteomic Tumor Analysis Consortium (CPTAC), under the auspices of National Cancer Institute's Office Proteomics Research, is a comprehensive and coordinated effort to accelerate understanding molecular basis cancer through application proteomic technologies workflows clinical tumor samples with characterized genomic transcript profiles. consortium analyzes biospecimens using mass spectrometry, identifying quantifying constituent proteins characterizing each sample's proteome....

10.1021/pr501254j article EN Journal of Proteome Research 2015-04-15

The integration of mass spectrometry-based proteomics with next-generation DNA and RNA sequencing profiles tumors more comprehensively. Here this "proteogenomics" approach was applied to 122 treatment-naive primary breast cancers accrued preserve post-translational modifications, including protein phosphorylation acetylation. Proteogenomics challenged standard cancer diagnoses, provided detailed analysis the ERBB2 amplicon, defined tumor subsets that could benefit from immune checkpoint...

10.1016/j.cell.2020.10.036 article EN cc-by-nc-nd Cell 2020-11-01

The toll-like receptor 7 and 8 (TLR7/8) agonist Resiquimod (R848) has been recognized as a promising immunostimulator for the treatment of cutaneous cancers in multiple clinical trials. However, systemic administration R848 often results strong immune-related toxicities while having limited therapeutic effects to tumor. In present study, prodrug-based nanocarrier delivery system was developed that exhibited high efficiency. conjugated α-tocopherol constitute an R848-Toco prodrug, followed by...

10.1016/j.jconrel.2019.06.003 article EN publisher-specific-oa Journal of Controlled Release 2019-06-04

Abstract Background As a metabolic reprogramming feature, cancer cells derive most of their energy from aerobic glycolysis, while its regulatory mechanisms and therapeutic strategies continue to be illusive. Methods Integrative analysis publically available expression profile datasets was used identify critical transcriptional regulators target glycolytic enzymes. The functions acting in were investigated by using vitro vivo assays. Kaplan–Meier curve log‐rank assay conduct the survival...

10.1002/ctm2.588 article EN cc-by Clinical and Translational Medicine 2021-11-01

Background: Hyaluronan (HA) is a ligand for the CD44 receptor which crucial to cancer cell proliferation and metastasis. High levels of expression in many cancers have encouraged development HA-based carriers anti-cancer therapeutics.Purpose: The objective this study was determine whether HA conjugation anticancer drugs impacts CD44-specific HA-drug uptake disposition by human head neck cells.Methods: internalization cellular hyaluronan-doxorubicin (HA-DOX), hyaluronan-cisplatin (HA-Pt),...

10.3109/1061186x.2014.921924 article EN Journal of drug targeting 2014-06-03

4 Background: Metastatic penile squamous cell carcinoma (mPSCC) is a rare and aggressive malignancy with limited treatment options. Standard systemic therapies include paclitaxel, ifosfamide, cisplatin (TIP), fluorouracil (5-FU + cis), paclitaxel monotherapy cetuximab. These regimens were evaluated as small single-arm studies. The HERCULES trial, phase 2 clinical study, demonstrated the safety efficacy of combining immunotherapy chemotherapy, signaling potential benefit immunotherapy. Our...

10.1200/jco.2025.43.5_suppl.4 article EN Journal of Clinical Oncology 2025-02-10

ABSTRACT Docosahexaenoic acid (DHA) and nervonic (NA) are the main components of brain gray white matter, respectively. Preclinical clinical studies suggest effects DHA or NA supplementation on memory improvement in aging Alzheimer's disease models. However, it is not yet clear whether dietary with can enhance by increasing their levels matter. The present study aimed to examine spatial matter lipidomic profiles adolescent mice without a NA‐enriched diet. Spatial conditional fear were...

10.1002/efd2.70059 article EN cc-by eFood 2025-05-08

New lymphatic imaging technologies are needed to better assess immune function and cancer progression treatment. Lymphatic uptake depends mainly on particle size (10-100 nm) charge. The of carriers for drug delivery can be optimized maximize uptake, localize chemotherapy metastases, enable visualization treatment deposition. Toward this end, female BALB/c mice were injected subcutaneously in the hind footpad or forearm with a series six different molecular weight hyaluronan (HA)...

10.3390/pharmaceutics4020276 article EN cc-by Pharmaceutics 2012-05-23
Coming Soon ...